These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 11384215)

  • 41. Perspective on live varicella vaccine.
    Gershon AA; Katz SL
    J Infect Dis; 2008 Mar; 197 Suppl 2():S242-5. PubMed ID: 18419404
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Varicella vaccination of immunocompromised children.
    Levin MJ
    J Infect Dis; 2008 Mar; 197 Suppl 2():S200-6. PubMed ID: 18419398
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunogenicity of Oka/Merck varicella vaccine in children vaccinated at 12-14 months of age versus 15-23 months of age.
    Silber JL; Chan IS; Wang WW; Matthews H; Kuter BJ
    Pediatr Infect Dis J; 2007 Jul; 26(7):572-6. PubMed ID: 17596796
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Development of varicella vaccine.
    Takahashi M; Asano Y; Kamiya H; Baba K; Ozaki T; Otsuka T; Yamanishi K
    J Infect Dis; 2008 Mar; 197 Suppl 2():S41-4. PubMed ID: 18419406
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Vaccination against herpes group viruses.
    Plotkin SA
    Pediatrics; 1975 Oct; 56(4):494-6. PubMed ID: 170580
    [No Abstract]   [Full Text] [Related]  

  • 46. Different genotype pattern of varicella-zoster virus obtained from patients with varicella and zoster in Germany.
    Sauerbrei A; Wutzler P
    J Med Virol; 2007 Jul; 79(7):1025-31. PubMed ID: 17516537
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA sequence analysis of varicella-zoster virus gene 62 from subclinical infections in healthy children immunized with the Oka varicella vaccine.
    Gomi Y; Ozaki T; Nishimura N; Narita A; Suzuki M; Ahn J; Watanabe N; Koyama N; Ushida H; Yasuda N; Nakane K; Funahashi K; Fuke I; Takamizawa A; Ishikawa T; Yamanishi K; Takahashi M
    Vaccine; 2008 Oct; 26(44):5627-32. PubMed ID: 18706951
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Varicella-zoster vaccine virus: evolution in action.
    Cohen JI
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):7-8. PubMed ID: 17185410
    [No Abstract]   [Full Text] [Related]  

  • 49. Varicella vaccine in clinical practice.
    Farquhar D
    CMAJ; 2001 May; 164(10):1485. PubMed ID: 11387927
    [No Abstract]   [Full Text] [Related]  

  • 50. Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule.
    American Academy of Pediatrics Committee on Infectious Diseases
    Pediatrics; 2007 Jul; 120(1):221-31. PubMed ID: 17606582
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection.
    Hammond O; Wang Y; Green T; Antonello J; Kuhn R; Motley C; Stump P; Rich B; Chirmule N; Marchese RD
    J Med Virol; 2006 Dec; 78(12):1679-87. PubMed ID: 17063506
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Identification of CD8+ T cell epitopes in the immediate early 62 protein (IE62) of varicella-zoster virus, and evaluation of frequency of CD8+ T cell response to IE62, by use of IE62 peptides after varicella vaccination.
    Frey CR; Sharp MA; Min AS; Schmid DS; Loparev V; Arvin AM
    J Infect Dis; 2003 Jul; 188(1):40-52. PubMed ID: 12825169
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Review of the Varilrix varicella vaccine.
    Chiu SS; Lau YL
    Expert Rev Vaccines; 2005 Oct; 4(5):629-43. PubMed ID: 16221065
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of concurrent administration of live attenuated influenza vaccine with measles-mumps-rubella and varicella vaccines to infants 12 to 15 months of age.
    Nolan T; Bernstein DI; Block SL; Hilty M; Keyserling HL; Marchant C; Marshall H; Richmond P; Yogev R; Cordova J; Cho I; Mendelman PM;
    Pediatrics; 2008 Mar; 121(3):508-16. PubMed ID: 18310199
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Molecular characterisation of varicella-zoster virus strains in Germany and differentiation from the Oka vaccine strain.
    Sauerbrei A; Eichhorn U; Gawellek S; Egerer R; Schacke M; Wutzler P
    J Med Virol; 2003 Oct; 71(2):313-9. PubMed ID: 12938208
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An evaluation of single nucleotide polymorphisms used to differentiate vaccine and wild type strains of varicella-zoster virus.
    Quinlivan M; Gershon AA; Steinberg SP; Breuer J
    J Med Virol; 2005 Jan; 75(1):174-80. PubMed ID: 15543576
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development of resistance to acyclovir during chronic infection with the Oka vaccine strain of varicella-zoster virus, in an immunosuppressed child.
    Levin MJ; Dahl KM; Weinberg A; Giller R; Patel A; Krause PR
    J Infect Dis; 2003 Oct; 188(7):954-9. PubMed ID: 14513413
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Natural selection for rash-forming genotypes of the varicella-zoster vaccine virus detected within immunized human hosts.
    Quinlivan ML; Gershon AA; Al Bassam MM; Steinberg SP; LaRussa P; Nichols RA; Breuer J
    Proc Natl Acad Sci U S A; 2007 Jan; 104(1):208-12. PubMed ID: 17182747
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Varlirix (GlaxoSmithKline).
    Arvin AM
    Curr Opin Investig Drugs; 2002 Jul; 3(7):996-9. PubMed ID: 12186278
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prospects for herpesvirus vaccination--safety and efficacy considerations.
    Parks WP; Rapp F
    Prog Med Virol; 1975; 21():188-206. PubMed ID: 174154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.